Eli Lilly and Co. is seeking emergency use authorization from the U.S. health regulator for the company’s experimental Covid-19 antibody monotherapy and plans to pursue a similar approval for a combination therapy with two of its antibody drugs in November 2020.

President Donald Trump was treated with an experimental antibody cocktail for Covid-19 and moved to a military hospital as a precautionary measure, White House officials said.

A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.

Eli Lilly and Co. has partnered with Amgen Inc. to increase the supply of the Indianapolis-based company’s experimental Covid-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.

Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.